S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:BMRN

BioMarin Pharmaceutical Stock Forecast, Price & News

$79.61
+0.51 (+0.64 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$78.81
Now: $79.61
$79.83
50-Day Range
$72.61
MA: $77.00
$80.40
52-Week Range
$68.25
Now: $79.61
$131.95
Volume611,738 shs
Average Volume1.76 million shs
Market Capitalization$14.45 billion
P/E Ratio18.22
Dividend YieldN/A
Beta0.67
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
BioMarin Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700
Employees3,001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.70 billion
Cash Flow$0.64 per share
Book Value$22.33 per share

Profitability

Net Income$-23,850,000.00

Miscellaneous

Market Cap$14.45 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$79.61
+0.51 (+0.64 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

How has BioMarin Pharmaceutical's stock price been impacted by Coronavirus?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BMRN stock has decreased by 8.4% and is now trading at $79.61.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of BioMarin Pharmaceutical?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioMarin Pharmaceutical
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BioMarin Pharmaceutical?

Wall Street analysts have given BioMarin Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioMarin Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for BioMarin Pharmaceutical
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported $4.01 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.01) by $4.02. The biotechnology company had revenue of $476.78 million for the quarter, compared to analyst estimates of $454.64 million. BioMarin Pharmaceutical had a net margin of 45.74% and a return on equity of 4.34%. BioMarin Pharmaceutical's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.30 EPS.
View BioMarin Pharmaceutical's earnings history
.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.81-1.87 billion, compared to the consensus revenue estimate of $1.86 billion.

What price target have analysts set for BMRN?

23 brokerages have issued twelve-month price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $77.00 to $218.00. On average, they expect BioMarin Pharmaceutical's stock price to reach $119.67 in the next year. This suggests a possible upside of 50.3% from the stock's current price.
View analysts' price targets for BioMarin Pharmaceutical
.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 67, Pay $3.6M)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 58, Pay $1.17M)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 62, Pay $1.55M)
  • Mr. Brian R. Mueller, Exec. VP & CFO (Age 46)
  • Ms. Andrea L. Acosta, Group VP & Chief Accounting Officer (Age 41)
  • Dr. C. Greg Guyer Ph.D., CTO and Exec. VP of Global Manufacturing & Technical Operations
  • Mr. Lon Cardon, Chief Scientific Strategy Officer
  • Traci McCarty, VP of Investor Relations
  • Mr. George Eric Davis, Exec. VP, Gen. Counsel & Sec. (Age 49)
  • Mr. Philip Lo Scalzo, Sr. VP & Chief Compliance Officer

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include UBS Asset Management Americas Inc. (1.11%), Nuveen Asset Management LLC (1.11%), Manning & Napier Group LLC (0.62%), First Trust Advisors LP (0.56%), Point72 Asset Management L.P. (0.52%) and California Public Employees Retirement System (0.50%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, David E I Pyott, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends for BioMarin Pharmaceutical
.

Which institutional investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Polar Capital LLP, Polar Capital LLP, Jennison Associates LLC, Victory Capital Management Inc., Westwood Holdings Group Inc., Calamos Wealth Management LLC, Nuveen Asset Management LLC, and First Trust Advisors LP. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, V Bryan Lawlis, and Willard H Dere.
View insider buying and selling activity for BioMarin Pharmaceutical
.

Which institutional investors are buying BioMarin Pharmaceutical stock?

BMRN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., UBS Asset Management Americas Inc., Rhenman & Partners Asset Management AB, Camber Capital Management LP, Natixis, Sofinnova Investments Inc., Manning & Napier Group LLC, and DekaBank Deutsche Girozentrale.
View insider buying and selling activity for BioMarin Pharmaceutical
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $79.61.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $14.45 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. BioMarin Pharmaceutical employs 3,001 workers across the globe.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is www.bmrn.com.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.